Literature DB >> 3037058

Itraconazole treatment of experimental systemic candidiasis in male rats.

M L Yozwiak, J N Galgiani.   

Abstract

After intravenous infection with Candida albicans, rats received daily doses of itraconazole for 3 days. All rats receiving 2.5 mg kg-1 day-1 survived while all rats receiving sham-treatment died. With subsequent reduction of the itraconazole dose to 0.63 mg kg-1 day-1, no survival occurred and mortality rates equalled those of the control group.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3037058     DOI： 10.1080/02681218780000171

Source DB:  PubMed          Journal:  J Med Vet Mycol        ISSN： 0268-1218


  4 in total

Review 1.  Overview of medically important antifungal azole derivatives.

Authors:  R A Fromtling
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

2.  In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent.

Authors:  T Tanio; K Ichise; T Nakajima; T Okuda
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis.

Authors:  R F Hector; E Yee
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

Review 4.  Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.